Fangzhou Honored with Golden Bull Award for Pioneering AI-Driven Chronic Disease Management
XIAMEN, China, Nov. 08, 2025 — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a prominent provider of AI-powered Internet healthcare solutions, was awarded the “Social Responsibility Golden Bull Award” on November 8, 2025. This recognition occurred at the 2025 Xiamen Industry Development Conference and Listed Companies (Hong Kong) Golden Bull Awards Ceremony, an event organized by the China Securities Journal.
The conference convened corporate leaders and investors to deliberate on how Hong Kong-listed companies can leverage innovation and robust governance to achieve sustainable global expansion. This year marked the inaugural presentation of the Golden Bull Awards specifically for Hong Kong-listed entities.
Fangzhou was recognized with the “Social Responsibility Golden Bull Award”
Fangzhou distinguished itself among its Hong Kong-listed counterparts to earn this accolade, demonstrating not only substantial revenue growth and solid profitability but also leadership in technological innovation and consistent creation of social value. The award underscores increasing confidence in the company’s “AI + chronic disease management” strategy — a rapidly expanding and high-impact sector that is actively reshaping China’s digital healthcare landscape.
Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, stated: “We are privileged to receive this award and remain committed to advancing AI-driven chronic disease management to deliver enduring benefits for public health.”
This recognition comes as China’s National Health Commission recently issued policy guidance promoting the application of “AI + Healthcare” as a key national development priority. In alignment with this directive, Fangzhou has developed an AI + H2H (Hospital-to-Home) ecosystem, integrating its proprietary XJ LLM and XS LLM to enhance precision, efficiency, and accessibility in chronic disease management.
In April of this year, Fangzhou and the Guangdong Provincial Institute of Liver Disease jointly established the “AI + Hepatitis Prevention and Control Training Center,” aimed at improving liver disease management through AI technology. In June, the Company participated in a rural revitalization initiative spearheaded by the Guangdong Communications Administration, contributing to the advancement of digital healthcare infrastructure in rural areas. More recently in October, Fangzhou launched the “AI + Psoriasis Management New Horizons” public education week, leveraging AI to broaden the reach and enhance the quality of health awareness campaigns.
Fangzhou has also led efforts in responsible AI governance, becoming the first Internet healthcare enterprise to join the “Human-Centered AI Development and Governance Initiative” this past July, contributing to high-level policy dialogue on AI–Internet integration. In October, the Company’s XJ LLM secured official national registration, highlighting Fangzhou’s dedication to regulatory compliance and establishing best practices across the medical AI field.
The Company continues to strengthen its leadership position in “AI + weight management,” collaborating with the China Food and Drug Institutions Quality and Safety Promotion Association to develop national standards for AI-enabled weight management. Fangzhou has also deepened its strategic collaboration with global pharmaceutical leader Novo Nordisk to jointly develop a digital intelligence ecosystem, combining medical expertise with AI-driven insights to advance the quality and accessibility of chronic disease management across China.
Looking ahead, Fangzhou will continue to build on its leadership as a premier Internet healthcare enterprise, advancing AI-powered chronic disease management while driving forward the industry’s overall development.
About China Securities Journal Golden Bull Awards
Established by the China Securities Journal and approved by national authorities, the Golden Bull Awards are recognized for their rigorous, transparent evaluation system and have become one of China’s most authoritative platforms for fostering positive interaction between industry and capital markets.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s foremost online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enhanced precision medicine solutions. For more information, visit .
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements
